Current State of Stereotactic Body Radiation Therapy for Genitourinary Malignancies

Overview

Journal Cancer J

Specialty Oncology

Date 2024 Nov 26

PMID 39589474

Authors

Alexander D Sherry

Neil Desai

Chad Tang

Affiliations

Soon will be listed here.

Abstract

Stereotactic body radiation therapy (SBRT) involves the delivery of high-dose, highly precise radiation therapy to focal sites of gross tumor involvement. Recent advances in radiation planning and image guidance have facilitated rapid growth in the evidence for and use of SBRT, particularly for genitourinary malignancies, where the underlying radiobiology often suggests greater tumor sensitivity to SBRT than to conventionally fractionated radiation. Here, we review the evolution of SBRT for patients with prostate adenocarcinoma and renal cell carcinoma. We discuss state-of-the-art trials, indications, and future directions in the SBRT-based management of both localized and metastatic disease. With rapidly growing enthusiasm and evidence, clinical and translational research efforts on the biology and outcomes of SBRT over the coming decade will be crucial to refining the indications, technical approach, and synergistic combinations of SBRT with highly active systemic therapies and improve the efficacy and quality-of-life outcomes for patients with genitourinary malignancies.

References

Royce T, Mavroidis P, Wang K, Falchook A, Sheets N, Fuller D . Tumor Control Probability Modeling and Systematic Review of the Literature of Stereotactic Body Radiation Therapy for Prostate Cancer. Int J Radiat Oncol Biol Phys. 2020; 110(1):227-236. PMC: 9445430. DOI: 10.1016/j.ijrobp.2020.08.014. View

Widmark A, Gunnlaugsson A, Beckman L, Thellenberg-Karlsson C, Hoyer M, Lagerlund M . Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet. 2019; 394(10196):385-395. DOI: 10.1016/S0140-6736(19)31131-6. View

De Cock L, Draulans C, Pos F, Isebaert S, De Roover R, van der Heide U . From once-weekly to semi-weekly whole prostate gland stereotactic radiotherapy with focal boosting: Primary endpoint analysis of the multicenter phase II hypo-FLAME 2.0 trial. Radiother Oncol. 2023; 185:109713. DOI: 10.1016/j.radonc.2023.109713. View

LLOYD-DAVIES R, Collins C, Swan A . Carcinoma of prostate treated by radical external beam radiotherapy using hypofractionation. Twenty-two years' experience (1962-1984). Urology. 1990; 36(2):107-11. DOI: 10.1016/0090-4295(90)80207-4. View

Foerster R, Zwahlen D, Buchali A, Tang H, Schroeder C, Windisch P . Stereotactic Body Radiotherapy for High-Risk Prostate Cancer: A Systematic Review. Cancers (Basel). 2021; 13(4). PMC: 7918664. DOI: 10.3390/cancers13040759. View

Burdett S, Boeve L, Ingleby F, Fisher D, Rydzewska L, Vale C . Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis. Eur Urol. 2019; 76(1):115-124. PMC: 6575150. DOI: 10.1016/j.eururo.2019.02.003. View

Morgan S, Hoffman K, Loblaw D, Buyyounouski M, Patton C, Barocas D . Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO, and AUA Evidence-Based Guideline. Pract Radiat Oncol. 2018; 8(6):354-360. DOI: 10.1016/j.prro.2018.08.002. View

Fowler J, Chappell R, Ritter M . Is alpha/beta for prostate tumors really low?. Int J Radiat Oncol Biol Phys. 2001; 50(4):1021-31. DOI: 10.1016/s0360-3016(01)01607-8. View

Folkert M, Zelefsky M, Hannan R, Desai N, Lotan Y, Laine A . A Multi-Institutional Phase 2 Trial of High-Dose SAbR for Prostate Cancer Using Rectal Spacer. Int J Radiat Oncol Biol Phys. 2021; 111(1):101-109. DOI: 10.1016/j.ijrobp.2021.03.025. View

10.

Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A . Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. J Clin Oncol. 2017; 36(5):446-453. DOI: 10.1200/JCO.2017.75.4853. View

11.

Zhang H, Orme J, Abraha F, Stish B, Lowe V, Lucien F . Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in C-Choline-PET/CT-Identified Oligometastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2021; 27(23):6376-6383. PMC: 8639778. DOI: 10.1158/1078-0432.CCR-21-2510. View

12.

Hannan R, Tumati V, Xie X, Cho L, Kavanagh B, Brindle J . Stereotactic body radiation therapy for low and intermediate risk prostate cancer-Results from a multi-institutional clinical trial. Eur J Cancer. 2016; 59:142-151. DOI: 10.1016/j.ejca.2016.02.014. View

13.

Fuller D, Wurzer J, Shirazi R, Bridge S, Law J, Crabtree T . Retreatment for Local Recurrence of Prostatic Carcinoma After Prior Therapeutic Irradiation: Efficacy and Toxicity of HDR-Like SBRT. Int J Radiat Oncol Biol Phys. 2019; 106(2):291-299. DOI: 10.1016/j.ijrobp.2019.10.014. View

14.

van As N, Yasar B, Griffin C, Patel J, Tree A, Ostler P . Radical Prostatectomy Versus Stereotactic Radiotherapy for Clinically Localised Prostate Cancer: Results of the PACE-A Randomised Trial. Eur Urol. 2024; 86(6):566-576. DOI: 10.1016/j.eururo.2024.08.030. View

15.

Wong H, Lee S, Chan A, Caini S, Hoskin P, Simone 2nd C . Stereotactic body radiation therapy versus conventional external beam radiotherapy for spinal metastases: A systematic review and meta-analysis of randomized controlled trials. Radiother Oncol. 2023; 189:109914. DOI: 10.1016/j.radonc.2023.109914. View

16.

Song X, Wei J, Sun R, Jiang W, Chen Y, Shao Y . Stereotactic Body Radiation Therapy Versus Conventional Radiation Therapy in Pain Relief for Bone Metastases: A Systematic Review and Meta-Analysis. Int J Radiat Oncol Biol Phys. 2022; 115(4):909-921. DOI: 10.1016/j.ijrobp.2022.10.017. View

17.

Ryu S, Deshmukh S, Timmerman R, Movsas B, Gerszten P, Yin F . Stereotactic Radiosurgery vs Conventional Radiotherapy for Localized Vertebral Metastases of the Spine: Phase 3 Results of NRG Oncology/RTOG 0631 Randomized Clinical Trial. JAMA Oncol. 2023; 9(6):800-807. PMC: 10119775. DOI: 10.1001/jamaoncol.2023.0356. View

18.

Folkert M, Timmerman R . Stereotactic ablative body radiosurgery (SABR) or Stereotactic body radiation therapy (SBRT). Adv Drug Deliv Rev. 2016; 109:3-14. DOI: 10.1016/j.addr.2016.11.005. View

19.

Siva S, Ost P, Ali M . The MIRAGE Trial-Optical Illusion or the Future of Prostate Stereotactic Radiotherapy?. JAMA Oncol. 2023; 9(3):373-375. DOI: 10.1001/jamaoncol.2022.6334. View

20.

Tang C, Msaouel P, Hara K, Choi H, Le V, Shah A . Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial. Lancet Oncol. 2021; 22(12):1732-1739. DOI: 10.1016/S1470-2045(21)00528-3. View